Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02858-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Kotaro Suzuki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Nuclear Medicine, Medical Oncology, Neoplasms, Health Policy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With the increasing importance of nuclear medicine therapy in overall cancer care and the introduction of 177 Lu-PSMA-617 to Japan being imminent, the Policy Recommendations for Promoting Nuclear Medicine Therapy in Japan from the Working Group for Promoting Nuclear Medicine Therapy of the Japan Society of Clinical Oncology (JSCO) aim to identify issues related to nuclear medicine therapy and propose measures to address them, in order to further advance nuclear medicine therapy in Japan. It is necessary to create an environment in which each medical institution can proactively introduce nuclear medicine therapy by taking measures that target discharge criteria, medical fees, and human resource development and link them organically. The Working Group believes that it is necessary to continue examining long-term issues taking into account the changes that have occurred since the introduction of 177 Lu-PSMA-617, as well as trends in nuclear medicine therapy other than 177 Lu-PSMA-617 that are expected to be introduced in the future. In addition, as the “Action Plans for Promoting the Production and Use of Medical Radioisotopes” have been formulated and the advancement of nuclear medicine therapy has become one of the nation’s major policy priorities, JSCO will continue to actively work with relevant ministries and local governments to resolve the various issues of nuclear medicine therapy, including the smooth introduction of 177 Lu-PSMA-617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. hmiyake@med.kobe-u.ac.jp.
- Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
- Department of Nuclear Medicine, Yokohama City University Hospital, Yokohama, Japan.
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Zitieren
APA
Suzuki, K., Miyake, H., Inaki, A., Takano, S., Kuboki, Y., Mizowaki, T., Nakamura, K., Ueno, M., Matsumoto, S., Obinata, D., Nakagawa, T., Murakami, M., Majima, Y., Yokono, M., Namba, M., & Yoshino, T. (2025). Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02858-3
Vancouver
Suzuki K, Miyake H, Inaki A, Takano S, Kuboki Y, Mizowaki T, et al. Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02858-3
BibTeX
@article{Suzuki2025,
author = {Suzuki, Kotaro and Miyake, Hideaki and Inaki, Anri and Takano, Shoko and Kuboki, Yasutoshi and Mizowaki, Takashi and Nakamura, Katsumasa and Ueno, Makoto and Matsumoto, Shigemi and Obinata, Daisuke and Nakagawa, Tohru and Murakami, Masato and Majima, Yoshiyuki and Yokono, Megumu and Namba, Masao and Yoshino, Takayuki},
title = {Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02858-3}
}
EUVIMED